Associate Professor Aaron Sverdlov

Director of Heart Failure

School of Medicine and Public Health

Email:aaron.sverdlov@newcastle.edu.au
Phone:(02) 4042 0725

Career Summary

Biography

Associate Professor Aaron Sverdlov is a cardiologist and clinician-scientist with proven track record in basic through to clinical research. His research interests encompass a broad spectrum of topics related to heart failure.

Personal statement

I am committed to improving management and outcomes for patients with heart failure through better understanding of mechanisms involved and discovering novel biomarkers and therapies.

Biography

Dr Sverdlov received his medical degree (MBBS) from the University of Adelaide, Australia in 2000. Then he completed his post-graduate training in general medicine and cardiology, including serving as a Chief Medical Resident for 2 years. He was admitted to the Fellowship of the Royal Australasian College of Physicians (FRACP) in December 2007, and then appointed staff specialist in cardiology at the Queen Elizabeth Hospital and Lyell McEwin Hospital from February 2008.

Aaron Sverdlov was awarded his PhD in 2012 from University of Adelaide. His doctoral work was on pathogenesis of aortic valve disease: Aaron led the aortic valve stenosis group at the Queen Elizabeth Hospital and provided the first evidence in humans that progression of aortic stenosis is amenable to treatment with renin-angiotensin-aldosterone system inhibitors. He was then awarded an NHMRC CJ Martin and RACP Fellowships to undertake postdoctoral work with Prof WS Colucci at Boston University (2012-15). There he studied mechanisms regulating cardiac function and energetics in models of metabolic heart disease/diastolic dysfunction utilizing state-of-the-art techniques and methodologies. He proved that mitochondrial ROS play a key pathogenic role in metabolic heart disease and identified reactive cysteines (never previously described) in mitochondrial complex II that modulate its function and lead to cardiac energetic impairment. He was also involved in describing a new method for quantitation of FDG PET/CT in cardiac sarcoidosis: this work has been heavily cited and this method has been adopted by a number of institutions. Aaron's postdoctoral work gained him a reputation as an expert and leader in mitochondrial redox field: he was awarded AHA Postdoctoral Fellowship.

Upon return to Australia in 2015, in partnership with his wife, A/Prof Doan Ngo, he established and co-led Cardiometabolic research group at the Basil Hetzel Institute in Adelaide. In 2 years they have attracted over $720,000 in research funding across a variety of cardiovascular areas, including obesity and angiogenesis, weight loss and exercise physiology, novel biomarkers and cardio-oncology.

Aaron relocated to Newcastle in 2017 where he was appointed as an Associate Professor and Director of Heart Failure at the University of Newcastle. He has a Clinical Academic appointment as a cardiologist at the John Hunter Hospital and is a Clinical Lead of Heart Failure Services for Hunter New England Local Health District.

Aaron has been awarded 4-year Heart Foundation Future Leader Fellowship for his research program "Bench-to-bedside approach to improving management and outcomes for patients with heart failure" commencing in January 2018.

Together with A/Prof Doan Ngo, Aaron has established the first-in-Australia bench-to-bedside "Cancer and the Heart" program combining basic and clinical research into cancer therapy-related cardiotoxicity with Calvary Mater Newcastle Hospital-based clinical outpatient service. This program is a collaboration between Cancer Network, Cardiology, Oncology, Haematology and Radiation oncology departments and is supported by the grants from the Heart Foundation of Australia and NSW Ministry of Health.

In November 2018, Aaron was a recipient of a Ministerial Award for Rising Stars in Cardiovascular Research.

Research Expertise

Aaron Sverdlov's research encompasses a full spectrum of translation from bench to bedside and service delivery. He has a basic and translational lab at the Hunter Medical Research Institute and shares a research lab with A/Prof Doan Ngo on the Callaghan Campus. His clinical research is at the John Hunter Hospital, Calvary Mater Newcastle and other sites across the Health District.

Broad goals of Aaron's research program are to improve care and health outcomes for patients with heart disease through better understanding of mechanisms responsible for development of heart failure, prevention and early detection of heart disease through development of novel biomarkers and improved delivery of healthcare by dedicated and integrated multidisciplinary approach.

Aaron's specific research interests directions are:

- mechanisms underlying development of heart failure, especially heart failure due to obesity and diabetes

- role of mitochondria and redox stress in heart failure

- mechanisms of development of cancer therapy-mediated cardiotoxicity

- role of novel biomarkers in early detection of various forms of heart disease

- basic and clinical factors reponsible for development and progression of aortic valve disease

- development and evaluation of integrated multidisciplinary heart failure service incorporating research and innovation

- development and evaluation of cardio-oncology clinical and translational program

- evaluation of new treatment options for patients with obesity, heart failure and chemotherapy-induced cardiotoxicity

Across these projects Aaron has a number of local, national and international collaborators.

Track record, peer review and service to the field

Aaron has over 50 career (since 2008) peer-reviewed publications and 4 book chapters (including chapters on Oxidative Stress in Heart Failure in the textbook “Heart Failure: A Companion to Braunwald’s Heart Disease”) with over 1100 citations and has had more than 80 presentations at international and national meetings. He received over 30 competitive grants, with >20 in the last 5 years (total >$2.5M AUD).

Aaron Sverdlov serves on the NHMRC's ECF Biomedical Panel (2015-6), NHMRC Cardiovascular Diseases GRP (2016-7) and NHMRC Ideas Grant Panel (2019); Heart Foundation of Australia Future Leader Fellowship (2019) and Postdoctoral Fellowships Committees (2017-8); Hunter New England Local Health District TRGS EOI review panel (2017); American Heart Association Cardiac Biology Program Peer Review Committee (2017-9) and Rebecca Cooper Medical Research Foundation grant advisory panel (2016).

He is also a reviewer for the European Society of Cardiology (ESC), Australian Research Council (ARC), Cardiac Society of Australia and New Zealand (CSANZ), Medical Research Council (UK), Croatian Science Foundation, Diabetes Australia, Medical Research Council UK (MRC), Singapore Ministry of Health and Society for Redox Biology and Medicine (SFRBM).

Aaron is an Associate Editor for Heart Lung and Circulation ans is on editorial board of Reactive Oxygen Species. He is a regular reviewer for multiple leading cardiovascular, pharmacology and basic science journals including Circulation Research, JACC, Hypertension, JMCC, International Journal of Cardiology, Antioxidant Redox Signaling, Cardiovascular Therapeutics and British Journal of Pharmacology.

Teaching and Education

Aaron has been involved in undergraduate teaching in medicine at the University of Newcastle and University of Adelaide as well as Boston University, USA. He supervised numerous clinical students and physician trainees especially in his capacity as the Chief Medical Resident. As a postdoctoral fellow at the Boston University he supervised and mentored honours, PhD and MD/PhD students. Currently he co-supervises 4 PhD, 4 honours students and 1 postdoctoral fellow across University of Newcastle, University of Adelaide and Flinders University of SA. He is involved in professional education of general practitioners and physicians in community and hospital settings.

Collaborations

In addition to multiple collaborations within University of Newcastle, HMRI and Hunter New England Local Health District, Aaron has active research collaborations with University of Adelaide, Flinders University of SA, University of Sydney, Boston University (USA) and University of East Anglia (UK).

Qualifications

Doctor of Philosophy, University of Adelaide
Bachelor of Medicine, Bachelor of Surgery, University of Adelaide

Keywords

Aortic valve stenosis
Biomarkers
Cardio-oncology
Cardiomyopathy
Clinical cardiology
Heart Failure
Mitochondria
Obesity and heart disease
Oxidative stress

Languages

English (Fluent)
Russian (Fluent)

Fields of Research

Code	Description	Percentage
110107	Metabolic Medicine	10
110201	Cardiology (incl. Cardiovascular Diseases)	80
111299	Oncology and Carcinogenesis not elsewhere classified	10

Professional Experience

UON Appointment

Title	Organisation / Department
Director of Heart Failure	University of Newcastle School of Medicine and Public Health Australia
Director of Heart Failure	Priority Research Centre (PRC) for Healthy Lungs \| The University of Newcastle School of Medicine and Public Health Australia
Director of Heart Failure	University of Newcastle School of Medicine and Public Health Australia

Academic appointment

Dates	Title	Organisation / Department
7/12/2017 -	Fellow - Heart Failure Association (FHFA) of the ESC	Heart Failure Association of the European Society of Cardiology France
1/11/2015 -	Fellow - American College of Cardiology (FACC)	American College of Cardiology United States
1/07/2014 - 15/04/2015	AHA Postdoctoral Fellow	Boston University MA Cardiovascular Medicine United States
1/01/2013 -	Fellow - European Society of Cardiology (FESC)	European Society of Cardiology France
1/07/2012 - 22/05/2017	NHMRC CJ Martin Fellow	University of Adelaide Australia
1/07/2012 - 15/04/2015	NHMRC CJ Martin Fellow	Boston University MA Cardiovascular Medicine United States
1/10/2011 -	Fellow - Cardiac Society of Australia and New Zealand (FCSANZ)	Cardiac Society of Australia and NewZealand Australia
17/12/2007 -	Fellow - Royal Australasian College of Physicians (FRACP)	The Royal Australasian College of Physicians Australia

Professional appointment

Dates	Title	Organisation / Department
1/01/2018 -	Clinical Lead - "Cancer and the Heart" (Cardio-oncology) program	Hunter New England Area Health Service Australia
1/07/2017 -	Clinical Lead - Heart Failure Service	Hunter New England Local Health District NSW Health Cardiovascular Medicine Australia
1/05/2017 -	Clinical Academic Cardiologist	John Hunter Hospital Cardiovascular Medicine Australia
1/07/2012 - 22/05/2017	Senior Staff Specialist - Cardiology	Queen Elizabeth Hospital Cardiology Department Australia
1/02/2008 - 30/06/2012	Staff Specialist - Cardiology	Queen Elizabeth Hospital Cardiology Department Australia

Teaching appointment

Dates	Title	Organisation / Department
1/01/2005 - 31/12/2006	Chief Medical Resident	Queen Elizabeth Hospital Department of Medicine Australia

Awards

Award

Year	Award
2018	2018 Ministerial Award for Rising Stars in Cardiovascular Research NSW Health

Grant Reviews

Year	Grant	Amount
2018	Singapore Translational Research Investigaor (STaR) Award C3231 - International Govt - Own Purpose - 3231, C3231 - International Govt - Own Purpose - 3231	$7,000,000
2018	MRC Project Grant - Medical Research Council C3232 - International Govt - Other - 3232, C3232 - International Govt - Other - 3232	$0
2018	Croation Science Foundation (HRZZ) - Project Grant C3232 - International Govt - Other - 3232, C3232 - International Govt - Other - 3232	$2,000,000
2018	American Heart Association - Cardiac Biology Program Peer Review Committee International - Competitive - 3IFA, International - Competitive - 3IFA	$0
2018	Heart Foundation Postdoctoral Fellowship Committee Aust Competitive - Non Commonwealth - 1NS, Aust Competitive - Non Commonwealth - 1NS	$0
2018	NHMRC Project Grant Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS	$0
2017	American Heart Association - Cardiac Biology Program Peer Review Committee International - Competitive - 3IFA, International - Competitive - 3IFA	$0
2017	NHMRC Cardiovascular GRP Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS	$0
2017	Heart Foundation Postdoctoral Fellowship Committee Aust Competitive - Non Commonwealth - 1NS, Aust Competitive - Non Commonwealth - 1NS	$0
2016	NHMRC ECF Committee Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS	$0
2016	NHMRC Cardiovascular GRP Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS	$0
2016	Rebecca L Cooper Medical Research Foundation Grant Review Committee Grant - Aust Non Government - 3AFG, Grant - Aust Non Government - 3AFG	$0
2015	NHMRC ECF Committee Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS	$0
2015	ARC Discovery Grants Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS	$0

Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Book (1 outputs)

Year	Citation	Altmetrics	Link
2010	Chirkov YY, Sverdlov AL, Horowitz JD, Beneficial effects of perhexiline in cardiovascular disease states (2010) © 2010 by Nova Science Publishers, Inc. All rights reserved. Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the ... [more] © 2010 by Nova Science Publishers, Inc. All rights reserved. Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline¿s reintroduction into clinical practice. This new book discusses the benefits of perhexiline in the treatment of cardiovascular disease.

Chapter (1 outputs)

Year	Citation	Altmetrics	Link
2016	Sawyer DB, Sverdlov AL, Colucci WS, 'Oxidative Stress in Heart Failure', Heart Failure A Companion to Braunwald's Heart Disease, Elsevier, Philadelphia 127-139 (2016)

Journal article (56 outputs)

Year

Citation

Altmetrics

Link

2019

Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ, 'Ibrutinib-related atrial fibrillation: A single center Australian experience.', Asia Pac J Clin Oncol, (2019)

DOI	10.1111/ajco.13179

2019

McGee M, Sugito S, Sverdlov AL, 'Cardiovascular Outcomes in Indigenous Australians: A National Gap', HEART LUNG AND CIRCULATION, 28 825-826 (2019)

DOI	10.1016/j.hlc.2019.04.001

2019

Brienesse SC, Sverdlov AL, 'Premature Ventricular Complexes: Benign, Pathogenic or Just a Marker of Myocardial Disease?', HEART LUNG AND CIRCULATION, 28 351-353 (2019)

DOI	10.1016/j.hlc.2019.01.001

2019

Luptak I, Qin F, Sverdlov AL, Pimentel DR, Panagia M, Croteau D, et al., 'Energetic Dysfunction Is Mediated by Mitochondrial Reactive Oxygen Species and Precedes Structural Remodeling in Metabolic Heart Disease.', Antioxid Redox Signal, (2019)

DOI	10.1089/ars.2018.7707

2019

Gopal DM, Ayalon N, Wang Y-C, Siwik D, Sverdlov A, Donohue C, et al., 'Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients.', J Am Heart Assoc, 8 e011100 (2019)

DOI	10.1161/JAHA.118.011100

2019

Ezad S, Al-Omary MS, Davies AJ, Leitch J, Sverdlov AL, Boyle AJ, 'Heart failure admissions following ST segment elevation myocardial infarction', Australian Journal of Rural Health, 27 99-100 (2019)

DOI	10.1111/ajr.12456
Co-authors	Andrew Boyle

2019

Ngo DTM, Sverdlov AL, Karki S, Macartney-Coxson D, Stubbs RS, Farb MG, et al., 'Oxidative modifications of mitochondrial complex ii are associated with insulin resistance of visceral fat in obesity', American Journal of Physiology - Endocrinology and Metabolism, 316 E168-E177 (2019) [C1]

© 2019 the American Physiological Society. Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been suggested as mechanisms of insulin resistance. The mechanism(s) behind this remains incompletely understood. In this study, we hypothesized that mitochondrial complex II dysfunction plays a role in impaired insulin sensitivity in visceral adipose tissue of subjects with obesity. We obtained subcutaneous and visceral adipose tissue biopsies from 43 subjects with obesity (body mass index = 30 kg/m 2 ) during planned bariatric surgery. Compared with subcutaneous adipose tissue, visceral adipose tissue exhibited decreased complex II activity, which was restored with the reducing agent dithiothreitol (5 mM) (P < 0.01). A biotin switch assay identified that cysteine oxidative posttranslational modifications (OPTM) in complex II subunit A (succinate dehydrogenase A) were increased in visceral vs. subcutaneous fat (P < 0.05). Insulin treatment (100 nM) stimulated complex II activity in subcutaneous fat (P < 0.05). In contrast, insulin treatment of visceral fat led to a decrease in complex II activity (P < 0.01), which was restored with addition of the mitochondria-specific oxidant scavenger mito-TEMPO (10 µ M). In a cohort of 10 subjects with severe obesity, surgical weight loss decreased OPTM and restored complex II activity, exclusively in the visceral depot. Mitochondrial complex II may be an unrecognized and novel mediator of insulin resistance associated with visceral adiposity. The activity of complex II is improved by weight loss, which may contribute to metabolic improvements associated with bariatric surgery.

DOI	10.1152/ajpendo.00227.2018
Citations	Web of Science - 1

2019

Al-Omary MS, Mcivor D, Sverdlov AL, 'Predicting Events in Heart Failure Patients: An Ongoing Challenge', HEART LUNG AND CIRCULATION, 28 195-197 (2019)

DOI	10.1016/j.hlc.2018.12.001

2018

Murtha L, Morten M, Schuliga M, Mabotuwana N, Hardy S, Waters D, et al., 'The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis', Aging and Disease, 10 (2018)

Citations	Scopus - 1
Co-authors	Darryl Knight, Lucy Murtha, Andrew Boyle, Michael Schuliga

2018

Luptak I, Sverdlov AL, Panagia M, Qin F, Pimentel DR, Croteau D, et al., 'Decreased ATP production and myocardial contractile reserve in metabolic heart disease.', Journal of molecular and cellular cardiology, 116 106-114 (2018) [C1]

DOI	10.1016/j.yjmcc.2018.01.017
Citations	Scopus - 4Web of Science - 5

2018

Efird JT, Jindal C, Kiser AC, Akhter SA, Crane PB, Kypson AP, et al., 'Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents', Journal of International Medical Research, 46 3183-3194 (2018) [C1]

© The Author(s) 2018. Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT). Administration of nitrates with antiplatelet agents reduces the conversion rate of cyclic guanosine monophosphate to guanosine monophosphate. This process is associated with increased concentrations of free radicals, catecholamines, and blood plasma volume. We hypothesized that patients undergoing CABG surgery who receive PINOT may be more susceptible to POAF when nitrates are administered with antiplatelet agents. Methods: Clinical records were examined from a prospectively maintained cohort of 4,124 patients undergoing primary isolated CABG surgery to identify POAF-associated factors. Results: POAF risk was increased among patients receiving PINOT, and the greatest effect was observed when nitrates were administered with antiplatelet therapy. Adjustment for comorbidities did not substantively change the study results. Conclusions: Administration of nitrates with certain antiplatelet agents was associated with an increased POAF risk among patients undergoing CABG surgery. Additional studies are needed to determine whether preventive strategies such as administration of antioxidants will reduce this risk.

DOI	10.1177/0300060518773934

2018

Al-Omary MS, Khan AA, Davies AJ, Fletcher PJ, Mcivor D, Bastian B, et al., 'Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014.', ESC heart failure, 5 271-278 (2018) [C1]

DOI	10.1002/ehf2.12239
Citations	Scopus - 2Web of Science - 2
Co-authors	John Attia, Christopher Oldmeadow, Andrew Boyle

2017

Patchett ND, Pawar S, Sverdlov A, Miller E, 'Does Improved Technology in SPECT Myocardial Perfusion Imaging Reduce Downstream Costs? An Observational Study', International Journal of Radiology and Imaging Technology, 3 (2017)

DOI	10.23937/2572-3235.1510023

2017

Amarasekera AT, Assadi-Khansari B, Liu S, Black M, Dymmott G, Rogers NM, et al., 'Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults', PLOS ONE, 12 (2017)

DOI	10.1371/journal.pone.0174435

2017

Sverdlov AL, Ngo DTM, 'Response to the letter to editor: Galectin-3 and atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 229 2-2 (2017)

DOI	10.1016/j.ijcard.2016.12.006

2016

Miller EJ, Calamaras T, Elezaby A, Sverdlov A, Qin F, Luptak I, et al., 'Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)

DOI	10.1161/JAHA.115.002277
Citations	Scopus - 2Web of Science - 2

2016

Sverdlov AL, Figtree GA, Horowitz JD, Ngo DTM, 'Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome', MEDIATORS OF INFLAMMATION, (2016)

DOI	10.1155/2016/8254590
Citations	Scopus - 1Web of Science - 1

2016

Sverdlov AL, Elezaby A, Qin F, Behring JB, Luptak I, Calamaras TD, et al., 'Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart Disease', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)

DOI	10.1161/JAHA.115.002555
Citations	Scopus - 30Web of Science - 30

2016

Chen D, Procter N, Goh V, Liu S, Chua SJ, Assadi-Khansari B, et al., 'New onset atrial fibrillation is associated with elevated galectin-3 levels', International Journal of Cardiology, 223 48-49 (2016) [C1]

DOI	10.1016/j.ijcard.2016.08.172
Citations	Scopus - 8Web of Science - 9

2016

Amarasekera AT, Sverdlov AL, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients', Diabetes and Metabolism, 42 378-381 (2016) [C1]

DOI	10.1016/j.diabet.2016.05.002
Citations	Scopus - 2Web of Science - 2

2015

Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, et al., 'High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 78 165-173 (2015) [C1]

DOI	10.1016/j.yjmcc.2014.07.018
Citations	Scopus - 38Web of Science - 37

2015

Yao C, Behring JB, Shao D, Sverdlov AL, Whelan SA, Elezaby A, et al., 'Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins', PLOS ONE, 10 (2015) [C1]

DOI	10.1371/journal.pone.0144025
Citations	Scopus - 14Web of Science - 15

2015

Taniguchi Y, Takahashi Y, Toba T, Yamada S, Yokoi K, Kobayashi S, et al., 'Poster Session 1: Sunday 3 May 2015, 08:30-18:00 * Room: Poster Area', European Heart Journal - Cardiovascular Imaging, 16 i11-i28 (2015)

DOI	10.1093/ehjci/jev051

2015

Horowitz JD, Chong C-R, Ngo DT, Sverdlov AL, 'Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?', JOURNAL OF THORACIC DISEASE, 7 E607-E611 (2015)

DOI	10.3978/j.issn.2072-1439.2015.12.40
Citations	Scopus - 3Web of Science - 3

2015

Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, et al., 'Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 79 275-283 (2015) [C1]

DOI	10.1016/j.yjmcc.2014.12.001
Citations	Scopus - 26Web of Science - 27

2014

Procter NEK, Chong C-R, Sverdlov AL, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics', SEMINARS IN THROMBOSIS AND HEMOSTASIS, 40 660-668 (2014)

DOI	10.1055/s-0034-1389082
Citations	Scopus - 6Web of Science - 6

2014

Chong C-R, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, et al., 'Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes', CARDIOVASCULAR DRUGS AND THERAPY, 28 347-360 (2014)

DOI	10.1007/s10557-014-6538-5
Citations	Scopus - 36Web of Science - 37

2014

Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al., 'Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis', JOURNAL OF NUCLEAR CARDIOLOGY, 21 925-939 (2014)

DOI	10.1007/s12350-014-9901-9
Citations	Scopus - 53Web of Science - 49

2014

Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of the Nitric Oxide System: Are We as Old as Our NO?', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (2014)

DOI	10.1161/JAHA.114.000973
Citations	Scopus - 17Web of Science - 16

2013

Chan WPA, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, et al., 'Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome', AMERICAN JOURNAL OF MEDICINE, 126 (2013) [C1]

DOI	10.1016/j.amjmed.2012.12.015
Citations	Scopus - 7Web of Science - 3

2013

Maher AR, Arif S, Madhani M, Abozguia K, Ahmed I, Fernandez BO, et al., 'Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite', BRITISH JOURNAL OF PHARMACOLOGY, 169 659-670 (2013) [C1]

DOI	10.1111/bph.12152
Citations	Scopus - 17Web of Science - 16

2013

Sverdlov AL, Chan WPA, Procter NEK, Chirkov YY, Ngo DTM, Horowitz JD, 'Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy', INTERNATIONAL JOURNAL OF CARDIOLOGY, 168 4624-4630 (2013)

DOI	10.1016/j.ijcard.2013.07.159
Citations	Scopus - 18Web of Science - 21

2013

Ngo DTM, Horowitz JD, Sverdlov AL, 'Heart Failure A Corin-Deficient State?', HYPERTENSION, 61 284-285 (2013)

DOI	10.1161/HYPERTENSIONAHA.112.196253
Citations	Scopus - 6Web of Science - 5

2013

Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, et al., 'Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?', CARDIOVASCULAR DRUGS AND THERAPY, 27 541-547 (2013)

DOI	10.1007/s10557-013-6481-x
Citations	Scopus - 12Web of Science - 6

2013

Dautov RF, Ngo DTM, Licari G, Liu S, Sverdlov AL, Ritchie RH, et al., 'The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 35 72-78 (2013)

DOI	10.1016/j.niox.2013.08.006
Citations	Scopus - 15Web of Science - 11

2012

Neil C, Thanh HN, Kucia A, Crouch B, Sverdlov A, Chirkov Y, et al., 'Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI', HEART, 98 1278-1284 (2012)

DOI	10.1136/heartjnl-2011-301481
Citations	Scopus - 43Web of Science - 42

2012

Ngo DT, Sverdlov AL, Horowitz JD, 'Prevention of aortic valve stenosis: A realistic therapeutic target?', PHARMACOLOGY & THERAPEUTICS, 135 78-93 (2012)

DOI	10.1016/j.pharmthera.2012.04.001
Citations	Scopus - 16Web of Science - 14

2012

Sverdlov AL, Ngo DT, Horowitz JD, 'Redefining the natural history of calcific aortic stenosis: lessons from Laennec', JOURNAL OF INTERNAL MEDICINE, 271 569-572 (2012)

DOI	10.1111/j.1365-2796.2012.02520.x

2012

Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD, 'Determinants of aortic sclerosis progression: Implications regarding impairment of nitric oxide signalling and potential therapeutics', European Heart Journal, 33 2419-2425 (2012) [C1]

DOI	10.1093/eurheartj/ehs171
Citations	Scopus - 18Web of Science - 16

2012

Neil CJ, Nguyen TH, Sverdlov AL, Chirkov YY, Chong C-R, Stansborough J, et al., 'Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history', EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 10 215-221 (2012)

Citations	Scopus - 18Web of Science - 10

2012

Sverdlov AL, Ngo DTM, Horowitz JD, 'Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2 43-49 (2012)

Citations	Web of Science - 3

2011

Ngo DTM, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, et al., 'Ramipril retards development of aortic valve stenosis in a rabbit model: Mechanistic considerations', British Journal of Pharmacology, 162 722-732 (2011) [C1]

DOI	10.1111/j.1476-5381.2010.01084.x
Citations	Scopus - 24Web of Science - 24

2011

Sverdlov AL, Ngo DT, Chapman MJ, Ali OA, Chirkov YY, Horowitz JD, 'Pathogenesis of aortic stenosis: not just a matter of wear and tear.', Am J Cardiovasc Dis, 1 185-199 (2011)

Citations	Web of Science - 11

2011

Nguyen TH, Neil CJ, Sverdlov AL, Mahadavan G, Chirkov YY, Kucia AM, et al., 'N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy', AMERICAN JOURNAL OF CARDIOLOGY, 108 1316-1321 (2011)

DOI	10.1016/j.amjcard.2011.06.047
Citations	Scopus - 64Web of Science - 57

2011

Ling L-H, Chik W, Averbuj P, Pati PK, Sverdlov AL, Ngo DTM, et al., 'Effects of Aging, Renal Dysfunction, Left Ventricular Systolic Impairment, and Weight on Steady State Pharmacokinetics of Perhexiline', THERAPEUTIC DRUG MONITORING, 33 251-256 (2011)

DOI	10.1097/FTD.0b013e31820dd8e9
Citations	Scopus - 4Web of Science - 4

2011

Nightingale AK, Sverdlov AL, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD, 'Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects', INTERNATIONAL JOURNAL OF CARDIOLOGY, 150 33-38 (2011)

DOI	10.1016/j.ijcard.2010.02.024
Citations	Scopus - 8Web of Science - 6

2011

Sverdlov AL, Ngo DTM, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, et al., 'The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 41-46 (2011)

DOI	10.1016/j.niox.2011.04.009
Citations	Scopus - 8Web of Science - 9

2011

Ngo DTM, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, et al., 'Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 326-330 (2011)

DOI	10.1016/j.niox.2011.06.005
Citations	Scopus - 38Web of Science - 31

2010

Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL, 'Modulation of myocardial metabolism: An emerging therapeutic principle', Current Opinion in Cardiology, 25 329-334 (2010)

DOI	10.1097/HCO.0b013e328339f191
Citations	Scopus - 35Web of Science - 34

2010

Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD, 'Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?', AMERICAN JOURNAL OF MEDICINE, 123 335-341 (2010)

DOI	10.1016/j.amjmed.2009.09.024
Citations	Scopus - 80Web of Science - 69

2010

Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Sage PR, Horowitz JD, 'Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure', CARDIOVASCULAR DRUGS AND THERAPY, 24 131-137 (2010)

DOI	10.1007/s10557-010-6233-0
Citations	Scopus - 8Web of Science - 6

2009

Ngo DTM, Sverdlov AL, McNeil JJ, Horowitz JD, 'Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine', PHARMACOLOGICAL RESEARCH, 60 503-507 (2009)

DOI	10.1016/j.phrs.2009.06.006
Citations	Scopus - 12Web of Science - 9

2009

Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD, 'Determinants of Occurrence of Aortic Sclerosis in an Aging Population', JACC-CARDIOVASCULAR IMAGING, 2 919-927 (2009)

DOI	10.1016/j.jcmg.2009.03.016
Citations	Scopus - 36Web of Science - 36

2008

Sverdlov AL, Taylor K, Elkington AG, Zeitz CJ, Beltrame JF, 'Cardiac magnetic resonance imaging identifies the elusive perivalvular abscess', CIRCULATION, 118 E1-E3 (2008)

DOI	10.1161/CIRCULATIONAHA.107.727339
Citations	Scopus - 2Web of Science - 2

2008

Ngo DTM, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, et al., 'Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein', EUROPEAN JOURNAL OF PHARMACOLOGY, 590 290-296 (2008)

DOI	10.1016/j.ejphar.2008.05.051
Citations	Scopus - 24Web of Science - 30

2008

Chan WPA, Sverdlov AL, Horowitz JD, 'Management of the metabolic syndrome in cardiovascular disease', Current Treatment Options in Cardiovascular Medicine, 10 27-38 (2008)

The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, ... [more]

The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, and proinflammatory and prothrombotic states. The clustering of these metabolic risk factors significantly increases the risk of type 2 diabetes and promotes vascular endothelial dysfunction, inflammation, and increased oxidative stress. The net result is an increase in the risk of atherosclerotic cardiovascular disease. Therefore, management of MS is of utmost importance, especially considering its rapidly increasing prevalence in a population with rising obesity rates and its significant cardiovascular implications. The primary management of this syndrome involves the correction of the underlying risk factors - obesity, physical inactivity, and an atherogenic diet - with lifestyle modifications including increased physical activity and dietary modification. Smoking cessation also should be encouraged. However, pharmacologic therapies are often required to address cardiovascular risk factors. These agents can be categorized broadly into 1) anorectic agents, 2) insulin-sensitizing agents, 3) statins, and 4) renin-angiotensin system antagonists. Emerging therapies include adipokines, endocannabinoid inhibitors, and metabolic modulators, such as perhexiline and trimetazidine. To date, these therapies have not been shown to normalize the metabolic and cardiovascular burden of MS, and there still is no single therapeutic agent for its management. Copyright © 2008 by Current Medicine Group LLC.

DOI	10.1007/s11936-008-0004-2
Citations	Scopus - 1

Show 53 more journal articles

Conference (33 outputs)

Year

Citation

Altmetrics

Link

2018

Chambers J, Elezaby A, Croteau D, Sverdlov A, Liesa M, Shirihai O, et al., 'ABCB10 deletion in cardiomyocytes leads to mitochondrial dysfunction and early death', FREE RADICAL BIOLOGY AND MEDICINE, Chicago, IL (2018)

DOI	10.1016/j.freeradbiomed.2018.10.007

2016

Chua SJ, Ajaero C, Assadi-Khansari B, McGavigan A, Horowitz JD, Sverdlov AL, Ngo DTM, 'Galectin 3 is markedly elevated in severe heart failure and predicts improvement in LV volumes post cardiac resynchronisation therapy', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)

2016

Assadi-Khansari B, Chua SJ, Chapman M, Ali O, Nguyen H, Horowitz JD, et al., 'Follistatin-like 3 predicts aortic root enlargement in patients with bicuspid aortic valve', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)

2016

Chua SJ, Ajaero C, Assadi-Khansari B, Mcgavigan A, Horowitz JD, Ngo DT, Sverdlov AL, 'Galectin 3 predicts improvement in LV volumes after Cardiac Resynchronisation Therapy', EUROPEAN JOURNAL OF HEART FAILURE (2016)

2016

Liu S, Assadi-Khansari B, Ajaero C, Chua SJ, Horowitz JD, Ngo DT, Sverdlov AL, 'Follistatin-Like 3 is Elevated In Acute Heart Failure Patients', CIRCULATION, Pentagon City, VA (2016)

2014

Sverdlov AL, Elezaby A, Qin F, Behring JB, Bachschmid MM, Luptak I, et al., 'Oxidative Protein Modifications Mediate Mitochondrial Dysfunction in Metabolic Heart Disease: Correction ex vivo and in vivo', CIRCULATION (2014)

2014

Luptak I, Sverdlov AL, Elezaby A, Miller EJ, Pimentel DR, Liesa M, et al., 'Western Diet for One Month Impairs Myocardial Energetics and Both Systolic and Diastolic Pump Function in the Mouse Heart', CIRCULATION (2014)

2014

Elezaby A, Sverdlov AL, Tu VH, Qin F, Rimer J, Schaffer JE, et al., 'Metabolic Remodeling in Mice with Cardiomyocyte-Specific Fatty Acid Overload', CIRCULATION (2014)

2013

Elezaby A, Sverdlov A, Tu V, Soni K, Liesa M, Liesa M, et al., 'Impairment of the PPARa/PGC1a Axis Compromises Mitochondrial Biogenesis and Function in Hearts With Cardiomyocyte-Specific Fatty Acid Transport Protein 1 (FATP1) Overexpression', CIRCULATION, Dallas, TX (2013)

2013

Amarasekera AT, Sverdlov AL, Roberts MS, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations; independent of vitamin D status', EUROPEAN HEART JOURNAL, Amsterdam, NETHERLANDS (2013)

Citations	Web of Science - 1

2012

Chan WP, Ngo DT, Sverdlov A, Chirkov YY, Horowitz JD, 'Effects of Ageing on Nitric Oxide Signalling in Women: Comparison with Polycystic Ovarian Syndrome', CIRCULATION (2012)

2012

Nguyen TH, Neil A, Sverdlov A, Ngo D, Chan W, Chirkov Y, et al., 'Paradoxical preservation of NO signalling in Takotsubo cardiomyopathy', EUROPEAN HEART JOURNAL, Munchen, GERMANY (2012)

2012

Dautov RF, Chirkov YY, Ngo DT, Sverdlov AL, Kemp-Harper BK, Ritchie RH, Horowitz JD, 'The Nitric Oxide Redox Sibling Nitroxyl Partially Circumvents Platelet Nitric Oxide Resistance in Patients With Ischaemic Heart Disease', CIRCULATION (2012)

2011

Sverdlov AL, Ngo DT, Chan WP, Chapman MJ, Chirkov YY, Gersh BJ, et al., 'Progression of Early Aortic Valve Disease: Are ACE Inhibitors Protective?', CIRCULATION (2011)

2011

Chan WPA, Sverdlov AL, Ngo DT, Rajendran S, Chirkov YY, Horowitz JD, 'Impact of ageing on the platelet and vascular responses in women with polycystic ovary syndrome', EUROPEAN HEART JOURNAL (2011)

2011

Chan WPA, Sverdlov AL, Ngo DT, Chirkov YY, Horowitz JD, 'Does oral contraceptive therapy induce platelet nitric oxide resistance?', EUROPEAN HEART JOURNAL (2011)

2011

Ngo DTM, Chan WPA, Sverdlov AL, Horowitz JD, 'Determinants and cardiovascular correlates of vitamin D deficiency in australian women', EUROPEAN HEART JOURNAL (2011)

2011

Sverdlov AL, Ngo DTM, Chirkov YY, Horowitz JD, 'Insights into the initiation of aortic stenosis: roles of ACE-inhibitors and vitamin D', EUROPEAN HEART JOURNAL (2011)

2011

Ngo DTM, Chan WPA, Sverdlov AL, Horowitz JD, 'Determinants and cardiovascular correlates of vitamin D deficiency in australian women', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

2011

Sverdlov AL, Ngo DTM, Chirkov YY, Horowitz JD, 'Insights into the initiation of aortic stenosis: roles of ACE-inhibitors and vitamin D', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

2010

Neil CJ, Nguyen TH, Collings S, Mahadavan D, Kucia AM, Sverdlov A, et al., 'Tako-Tsubo Cardiomyopathy: a Slowly Resolving Pancarditis', CIRCULATION (2010)

2010

Sverdlov AL, Ngo DT, Nightingale AK, Rajendran S, Ritchie RH, Marwick TH, et al., 'Relationship between LV mass and diastolic function is independent of NO generation', EUROPEAN HEART JOURNAL, Stockholm, SWEDEN (2010)

2010

Chan WP, Ngo DT, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, et al., 'Implications of insulin sensitivity on inflammatory activation and atherogenic risk in normal and PCOS females', EUROPEAN HEART JOURNAL, Stockholm, SWEDEN (2010)

2009

Sverdlov AL, Ngo DT, Nightingale AK, Rajendran S, Heresztyn T, Horowitz JD, 'Plasma Concentrations of Asymmetric Dimethylarginine (ADMA) Predict LV Mass Independent of Afterload', CIRCULATION, Orlando, FL (2009)

2009

Ngo DTM, Sverdlov AL, Mcneil JJ, Horowitz JD, 'Low 25-hydroxyvitamin D levels are associated with elevated plasma ADMA and C-reactive protein concentrations: nexus with cardiovascular disease', EUROPEAN HEART JOURNAL (2009)

2008

Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Horowitz JD, 'Is there a pharmacological hydralazine/nitrate interaction in chronic heart failure?', EUROPEAN HEART JOURNAL (2008)

Citations	Web of Science - 1

2007

Ngo DT, Stafford I, Wuttke RD, Weedon H, Smith MD, Kelly DJ, et al., 'Ramipril retards development of aortic valve stenosis in a rabbit model: Role of thioredoxin interacting protein', CIRCULATION, Orlando, FL (2007)

2007

Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, Mcneil JJ, Horowitz JD, 'Aortic valve sclerosis is associated with impaired platelet responsiveness to nitric oxide', EUROPEAN HEART JOURNAL (2007)

2007

Ngo DTM, Stafford I, Wuttke RD, Weedon H, Smith MD, Sverdlov AL, et al., 'Ramipril retards progression of aortic valve stenosis: association with preservation of nitric oxide effects', EUROPEAN HEART JOURNAL (2007)

2006

Nightingale AK, Rajendran S, Sverdlov A, Mishra K, Ngo D, Heresztyn T, Horowitz JD, 'Aortic sclerosis precedes development of systemic endothelial dysfunction', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)

2006

Ngo DT, Wuttke RD, Stafford I, Rosenkranz AR, Sverdlov AL, Chirkov YY, et al., 'Effects of vitamin D2 supplementation on aortic valvular and vascular endothelial functions in a rabbit model of aortic stenosis', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)

2006

Chirkov YY, Rajendran S, Sverdlov AL, Horowitz JD, 'Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1-7) is mediated by its specific receptor and is associated with the suppression of superoxide release', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)

2006

Ngo DT, Wuttke RD, Weedon H, Nightingale AK, Sverdlov AL, Kennedy JA, Horowitz JD, 'Vitamin D2 supplementation induces aortic stenosis in rabbits', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)

Show 30 more conferences

Edit

Grants and Funding

Summary

Number of grants	36
Total funding	$3,009,253

Click on a grant title below to expand the full details for that specific grant.

20193 grants / $75,063

Better understanding of mechanisms underlying heart failure due to obesity$50,000

Funding body: Royal Australasian College of Physicians

Funding body	Royal Australasian College of Physicians
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Foundation for High Blood Pressure Research Establishment Fellowship
Role	Lead
Funding Start	2019
Funding Finish	2019
GNo	G1801367
Type Of Funding	C3112 - Aust Not for profit
Category	3112
UON	Y

Novel discovery of Sirtuin-3 isoforms in human cardiomyocytes$20,063

Funding body: John Hunter Hospital Charitable Trust

Funding body	John Hunter Hospital Charitable Trust
Project Team	Associate Professor Aaron Sverdlov, Ms Amanda Croft, Associate Professor Doan Ngo
Scheme	Research Grant
Role	Lead
Funding Start	2019
Funding Finish	2019
GNo	G1900118
Type Of Funding	C2220 - Aust StateTerritoryLocal - Other
Category	2220
UON	Y

Improving management and outcomes for patients with cancer therapy-induced cardiotoxicity$5,000

Funding body: National Heart Foundation of Australia

Funding body	National Heart Foundation of Australia
Project Team	Associate Professor Aaron Sverdlov
Scheme	2018 Ministerial Award for Rising Stars in Cardiovascular Research
Role	Lead
Funding Start	2019
Funding Finish	2019
GNo	G1900528
Type Of Funding	C3112 - Aust Not for profit
Category	3112
UON	Y

20187 grants / $735,747

Improving Outcomes Following Hospitalisation for Heart Failure in Regional and Remote NSW – the BEEM-HF Trial$479,376

Funding body: NSW Ministry of Health

Funding body	NSW Ministry of Health
Project Team	A/Prof Aaron Sverdlov, Prof Andrew Boyle, Dr James Leitch, Dr Maged William, Prof John Attia, Prof John Wiggers, Ms Dawn McIvor, Mr Lindsay Savage, Ms Julie Rutherford, A/Prof Doan Ngo
Scheme	Translational Research Grant Scheme (TRGS)
Role	Lead
Funding Start	2018
Funding Finish	2020
GNo
Type Of Funding	C2220 - Aust StateTerritoryLocal - Other
Category	2220
UON	N

To develop and test a new paradigm for management of changing Heart Failure disease treatment$99,371

Funding body: Biotronik Australia Pty Ltd

Funding body	Biotronik Australia Pty Ltd
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor Andrew Boyle
Scheme	Entrepreneurs' Programme: Innovation Connections
Role	Lead
Funding Start	2018
Funding Finish	2018
GNo	G1801209
Type Of Funding	C3111 - Aust For profit
Category	3111
UON	Y

Predicting tOxicity for Myeloma Therapy (PrOMT)$50,000

Funding body: Hunter Medical Research Institute

Funding body	Hunter Medical Research Institute
Project Team	Doctor Anoop Enjeti, Doctor Wojt Janowski, Doctor Chen Chen Jiang, Associate Professor Aaron Sverdlov
Scheme	Project Grant
Role	Investigator
Funding Start	2018
Funding Finish	2018
GNo	G1900030
Type Of Funding	C3120 - Aust Philanthropy
Category	3120
UON	Y

Health Economic analyses for BEEM-HF trial$40,000

Funding body: Hunter New England Local Health District

Funding body	Hunter New England Local Health District
Project Team	A/Prof Aaron Sverdlov, A/Prof Andrew Searles
Scheme	2018 HNE MRSP
Role	Lead
Funding Start	2018
Funding Finish	2020
GNo
Type Of Funding	Other Public Sector - Local
Category	2OPL
UON	N

Identification of novel biomarkers to predict early onset chemotherapy-induced cardiovascular toxicities$37,000

Funding body: Hunter Medical Research Institute

Funding body	Hunter Medical Research Institute
Project Team	Associate Professor Doan Ngo, Associate Professor Aaron Sverdlov, Dr Anoop Enjeti, Prof Philip Rowlings, Associate Professor Anthony Proietto
Scheme	Project Grant
Role	Investigator
Funding Start	2018
Funding Finish	2018
GNo	G1801448
Type Of Funding	C3120 - Aust Philanthropy
Category	3120
UON	Y

Determining the mechanisms of myocardial infarction induced cardiac fibrosis: what role does fibulin-3 play?$25,000

Funding body: Hunter Medical Research Institute

Funding body	Hunter Medical Research Institute
Project Team	Doctor Lucy Murtha, Professor Andrew Boyle, Associate Professor Doan Ngo, Associate Professor Aaron Sverdlov
Scheme	Project Grant
Role	Investigator
Funding Start	2018
Funding Finish	2018
GNo	G1801370
Type Of Funding	C3120 - Aust Philanthropy
Category	3120
UON	Y

Statistical analyses for BEEM-HF trial$5,000

Funding body: Hunter New England Local Health District

Funding body	Hunter New England Local Health District
Project Team	A/Prof Aaron Sverdlov; CREDITTS group
Scheme	HRTC
Role	Lead
Funding Start	2018
Funding Finish	2020
GNo
Type Of Funding	Other Public Sector - Local
Category	2OPL
UON	N

20177 grants / $738,620

Bench-to-bedside approach to improving management and outcomes for patients with heart failure$521,620

Funding body: National Heart Foundation of Australia

Funding body	National Heart Foundation of Australia
Project Team	Associate Professor Aaron Sverdlov
Scheme	Future Leader Fellowship
Role	Lead
Funding Start	2017
Funding Finish	2021
GNo	G1700785
Type Of Funding	Aust Competitive - Non Commonwealth
Category	1NS
UON	Y

Cardiometabolic research program$100,000

Funding body: Hunter New England Local Health District

Funding body	Hunter New England Local Health District
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Project Grant
Role	Lead
Funding Start	2017
Funding Finish	2017
GNo	G1701207
Type Of Funding	C3112 - Aust Not for profit
Category	3112
UON	Y

Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000

Funding body: National Heart Foundation of Australia

Funding body	National Heart Foundation of Australia
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz, AM
Scheme	Vanguard Grant
Role	Lead
Funding Start	2017
Funding Finish	2017
GNo	G1701324
Type Of Funding	Aust Competitive - Non Commonwealth
Category	1NS
UON	Y

Equipment Grant - Vevo 1100 Imaging System$20,000

Woodend Foundation Funding for Surgical and Clinical Research Equipment

Funding body: Faculty of Health and Medicine, University of Newcastle

Funding body	Faculty of Health and Medicine, University of Newcastle
Scheme	Faculty Grant
Role	Lead
Funding Start	2017
Funding Finish	2017
GNo
Type Of Funding	Internal
Category	INTE
UON	N

Assessing the feasibility of angiotensin receptor blocker/neprilysin inhibitor (ARNI) in reducing the progression of aortic valve stenosis$10,000

Funding body: Universtiy of Newcastle

Funding body	Universtiy of Newcastle
Scheme	Linkage Pilot Grant
Role	Lead
Funding Start	2017
Funding Finish	2018
GNo
Type Of Funding	Internal
Category	INTE
UON	N

EMCR EQUIPMENT GRANT$10,000

Funding body: Hunter Medical Research Institute (HMRI)

Funding body	Hunter Medical Research Institute (HMRI)
Scheme	Unknown
Role	Lead
Funding Start	2017
Funding Finish	2017
GNo
Type Of Funding	Internal
Category	INTE
UON	N

Dissecting hypertrophic pathways in obesity-mediated heart failure$2,000

Funding body: Faculty of Health and Medicine Pilot Grant University of Newcastle

Funding body	Faculty of Health and Medicine Pilot Grant University of Newcastle
Scheme	UON Faculty of Health and Medicine Pilot Grant
Role	Lead
Funding Start	2017
Funding Finish	2017
GNo
Type Of Funding	Internal
Category	INTE
UON	N

20165 grants / $224,516

Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000

Funding body: National Heart Foundation of Australia

Funding body	National Heart Foundation of Australia
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz
Scheme	Vanguard Grant
Role	Lead
Funding Start	2016
Funding Finish	2018
GNo
Type Of Funding	Aust Competitive - Non Commonwealth
Category	1NS
UON	N

Regulators of the novel anti-angiogenic isoform: VEGF-A165b in obesity$60,000

Funding body: Diabetes Australia

Funding body	Diabetes Australia
Project Team	Associate Professor Doan Ngo (Lead), Associate Professor Aaron Sverdlov
Scheme	Research Grant
Role	Investigator
Funding Start	2016
Funding Finish	2017
GNo
Type Of Funding	Aust Competitive - Non Commonwealth
Category	1NS
UON	N

Early detection of chemotherapy-induced cardiomyopathy$50,000

Funding body: Royal Australasian College of Physicians

Funding body	Royal Australasian College of Physicians
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Research Establishment Award
Role	Lead
Funding Start	2016
Funding Finish	2018
GNo
Type Of Funding	Grant - Aust Non Government
Category	3AFG
UON	N

Metabolic heart disease: markers and mechanisms$25,000

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body	Rebecca L Cooper Medical Research Foundation Ltd
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Research Grant
Role	Lead
Funding Start	2016
Funding Finish	2017
GNo	G1701494
Type Of Funding	C3112 - Aust Not for profit
Category	3112
UON	Y

Are mitochondrial reactive oxygen species key mediators of metabolic syndrome-induced heart disease$14,516

Funding body: The University of Adelaide

Funding body	The University of Adelaide
Scheme	Shared
Role	Lead
Funding Start	2016
Funding Finish	2016
GNo
Type Of Funding	Internal
Category	INTE
UON	N

20152 grants / $470,000

Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$450,000

Awarded but not accepted

Funding body: The University of Sydney

Funding body	The University of Sydney
Scheme	-
Role	Lead
Funding Start	2015
Funding Finish	2017
GNo
Type Of Funding	Grant - Aust Non Government
Category	3AFG
UON	N

Start up grant$20,000

Funding body: University of Adelaide

Funding body	University of Adelaide
Scheme	Unknown
Role	Lead
Funding Start	2015
Funding Finish	2015
GNo
Type Of Funding	Internal
Category	INTE
UON	N

20141 grants / $130,000

Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$130,000

Funding body: American Heart Association

Funding body	American Heart Association
Scheme	Postdoctoral Fellowship
Role	Lead
Funding Start	2014
Funding Finish	2015
GNo
Type Of Funding	International - Competitive
Category	3IFA
UON	N

20131 grants / $3,100

Keystone Symposium Travel Grant$3,100

Funding body: The University of Adelaide

Funding body	The University of Adelaide
Scheme	Travel Grant
Role	Lead
Funding Start	2013
Funding Finish	2013
GNo
Type Of Funding	Internal
Category	INTE
UON	N

20125 grants / $481,107

Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$435,257

Funding body: NHMRC (National Health & Medical Research Council)

Funding body	NHMRC (National Health & Medical Research Council)
Project Team	A/Prof Aaron Sverdlov
Scheme	Early Career Fellowships
Role	Lead
Funding Start	2012
Funding Finish	2017
GNo
Type Of Funding	Aust Competitive - Commonwealth
Category	1CS
UON	N

Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$20,000

Funding body: Royal Australasian College of Physicians

Funding body	Royal Australasian College of Physicians
Scheme	Margorie Hooper Fellowship
Role	Lead
Funding Start	2012
Funding Finish	2013
GNo
Type Of Funding	Grant - Aust Non Government
Category	3AFG
UON	N

Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$15,000

Funding body: Medtronic

Funding body	Medtronic
Scheme	Postdoctoral project funding
Role	Lead
Funding Start	2012
Funding Finish	2017
GNo
Type Of Funding	Donation - Aust Non Government
Category	3AFD
UON	N

Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$10,000

Funding body: Boston Scientific

Funding body	Boston Scientific
Scheme	Postdoctoral project funding
Role	Lead
Funding Start	2012
Funding Finish	2017
GNo
Type Of Funding	Donation - Aust Non Government
Category	3AFD
UON	N

Travel Award$850

Funding body: Seahorse Bioscience

Funding body	Seahorse Bioscience
Scheme	Travel Award
Role	Lead
Funding Start	2012
Funding Finish	2012
GNo
Type Of Funding	International - Non Competitive
Category	3IFB
UON	N

20092 grants / $4,500

AHA 2009 Traveling Fellowship$3,000

Funding body: Cardiac Society of Australia and NewZealand

Funding body	Cardiac Society of Australia and NewZealand
Scheme	Travelling Fellowship
Role	Lead
Funding Start	2009
Funding Finish	2009
GNo
Type Of Funding	Grant - Aust Non Government
Category	3AFG
UON	N

Small Grant$1,500

Funding body: Heart Foundation

Funding body	Heart Foundation
Scheme	E O Myers Trust Fund Grant
Role	Lead
Funding Start	2009
Funding Finish	2009
GNo
Type Of Funding	Aust Competitive - Non Commonwealth
Category	1NS
UON	N

20082 grants / $61,600

Pathogenesis of aortic valve sclerosis$55,000

Funding body: CVL - Pfiser

Funding body	CVL - Pfiser
Scheme	Unknown
Role	Lead
Funding Start	2008
Funding Finish	2008
GNo
Type Of Funding	Grant - Aust Non Government
Category	3AFG
UON	N

Equipment grant$6,600

Funding body: Heart Foundation

Funding body	Heart Foundation
Scheme	J Fund Grant
Role	Lead
Funding Start	2008
Funding Finish	2008
GNo
Type Of Funding	Aust Competitive - Non Commonwealth
Category	1NS
UON	N

20051 grants / $85,000

Pathogenesis of aortic valve stenosis$85,000

Funding body: The University of Adelaide

Funding body	The University of Adelaide
Scheme	Faculty of Health Sciences Divisional PhD Scholarship
Role	Lead
Funding Start	2005
Funding Finish	2010
GNo
Type Of Funding	Internal
Category	INTE
UON	N

Edit

Research Supervision

Number of supervisions

Completed0

Current8

Current Supervision

Commenced	Level of Study	Research Title	Program	Supervisor Type
2019	PhD	Pathophysiology of Obesity-Induced Cardiometabolic Dysfunction: The Link With Colorectal Cancer	PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle	Co-Supervisor
2018	PhD	Heart Failure Outcomes in Hunter New England Area	PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle	Co-Supervisor
2018	PhD	Early Detection of Cardiotoxicity from Chemotherapy	PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle	Co-Supervisor
2017	PhD	Establishment and Evaluation of a nurse-led cardio-oncology Unit	Nursing, Flinders University	Co-Supervisor
2017	Post-Doctoral Fellowship	Heart Failure pathophysiology and novel biomarkers	Medical Science, University of Adelaide	Co-Supervisor
2017	Post-Doctoral Fellowship	Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?	Medical Science, School of Medicine & Public Health, Faculty of Health & Medicine, University of Newcastle \| Australia	Principal Supervisor
2017	Honours	Heart failure: novel biomarkers	Medical Science, University of Adelaide	Co-Supervisor
2016	PhD	The Use of N-acetylcysteine and Ramipril to improve clinical outcomes in Tako Tsubo Cardiomyopathy	Medical Science, University of Adelaide	Co-Supervisor

Edit

Research Opportunities

Early Detection of Chemotherapy-induced Cardiotoxicity

PhD

PHD

Faculty of Health and Medicine

1/01/2018 - 31/12/2020

Contact

Associate Professor Aaron Sverdlov
University of Newcastle
School of Medicine and Public Health
aaron.sverdlov@newcastle.edu.au

Edit

News

Heart failure researcher named 2018 rising star

November 7, 2018

Newcastle researchers awarded $750,000 to help heart health

December 11, 2017

Six Hunter researchers have secured $750,000 in Heart Foundation funding to investigate heart disease, Australia’s leading cause of death.